High Cholesterol Treatment in Johor Bahru

Almost every week someone arrives holding a lipid report with one line circled, wanting to know whether that figure is bad. The honest answer is that the figure on its own means very little. Consider two people who walk in on the same afternoon with an identical LDL result. The first is thirty-one, does not smoke, has an unremarkable blood pressure, no diabetes, and no relative who has ever had a heart problem before old age. The second is fifty-eight, smokes half a pack a day, has had diabetes for eleven years, takes two tablets for blood pressure, and lost a brother to a heart attack at fifty-one. The number on the page is the same. The correct management is not remotely the same. This is the single most important idea on this page. Cholesterol is not a disease you either have or do not have. It is one input into an estimate of how likely you are to have a heart attack or stroke over the coming years, and that estimate draws on your age, your sex, whether you smoke, your blood pressure, your blood sugar, your kidney function, your family history, and above all whether you already have narrowed arteries anywhere in your body. Someone who has had a stent or a stroke sits in an entirely different category from someone being screened for the first time. So we are not scoring your number against a fixed pass mark. We are asking what it is doing inside your particular body over your remaining decades, which is why we will ask about your father and your brothers before we say anything about tablets.

A standard lipid profile reports four things, and increasingly a fifth that we pay more attention to than most patients realise. Total cholesterol is the sum of everything, and the least useful line on the report. It bundles the fractions that cause harm together with the fraction that does not, so a person can have a flattering total and an unflattering distribution, or the reverse. LDL cholesterol is the fraction that carries cholesterol out to the tissues and deposits it into artery walls. When people speak of cholesterol clogging arteries, LDL is what they are describing, and lowering it is the mechanism by which most of our medications work. HDL cholesterol carries cholesterol back towards the liver. A higher HDL is associated with lower risk, but attempts to raise it with drugs have repeatedly failed to reduce heart attacks, which tells us HDL is more a marker of a healthy metabolic state than a lever to pull. Do not chase it. Triglycerides are a separate class of fat entirely, extremely responsive to what you ate and drank recently, and closely tied to insulin resistance, abdominal weight and alcohol. They deserve their own discussion further down. Then there is non-HDL cholesterol, which is simply total cholesterol minus HDL. It captures every cholesterol-carrying particle capable of lodging in an artery wall, not just LDL. When triglycerides are high, the LDL figure on many reports is calculated rather than measured and becomes unreliable, and it also misses the harmful remnant particles riding alongside. That is exactly the situation in most people with diabetes, prediabetes or central obesity, which describes a great many of our patients. In them, non-HDL is the better guide, and it costs nothing extra to work out. Lipoprotein(a), written Lp(a), is a largely inherited particle measured on a separate test. It is not part of the routine panel, it barely responds to diet, and a raised level helps explain heart disease in families where the ordinary numbers look innocent.

There is an inherited condition in which the body is genetically poor at clearing LDL from the blood, and the person has been carrying a markedly elevated level since childhood rather than acquiring it in middle age from diet. It is called familial hypercholaesterolaemia, and it is not rare. Population studies across many countries put it at roughly one in two to three hundred people, which in a district our size means it is sitting in our waiting room regularly. Most people carrying it in Malaysia have never been told. Why this matters so much is arithmetic. Damage accumulates with exposure over time, so someone who has had a very high level since the age of five arrives at forty with decades of accumulated burden that an ordinary risk calculator badly underestimates. Untreated, a substantial proportion suffer coronary events far earlier than they should. Treated from early adulthood, their outlook is close to normal. What makes us suspect it? A strikingly high LDL, particularly one that barely moves despite genuine dietary effort. Heart attack, stent, bypass or sudden cardiac death in a parent, sibling, uncle or grandparent at an age that felt shockingly young. Firm nodular thickening over the Achilles tendon or the knuckle tendons on the back of the hand, called tendon xanthomata. Yellowish deposits around the eyelids. A grey or white ring at the edge of the cornea in someone under about forty-five, unremarkable in the elderly but a genuine signal in the young. Then the part routinely neglected: if one person in a family has it, each first-degree relative has a one in two chance of carrying it too. Testing the parents, siblings and children of an affected person is called cascade testing, and it is the highest-yield screening any of us can do. A single lipid profile in a nineteen-year-old nephew can alter the rest of his life. If your family has a story of young hearts failing, bring that story here.

Dietary advice fails here when it is delivered as a list of forbidden foods, because nobody sustains a life in which they never eat what everyone around them eats. Weddings, kenduri, Sunday breakfast with the family, supper after a late shift — food is social, and advice that ignores that gets discarded on the drive home. So we talk about three things instead: how often, how much, and what goes in its place. Santan is the honest starting point. Coconut milk is high in saturated fat and central to rendang, lemak, laksa and much of what makes local cooking taste like home. Nobody is asking you to abandon it. What changes outcomes is frequency and volume: a lemak dish two or three times a week rather than daily, gravy spooned lightly over rice rather than the rice swimming in it, and at home, diluting santan with water or replacing part of it with evaporated milk where the difference is barely noticeable. Deep-fried food behaves the same way — ayam goreng once a week is a different proposition from fried food at two meals a day. Roti canai deserves specific mention because patients rarely count it. The dough is worked with ghee or margarine and cooked on a greased griddle, so the fat is inside the bread, not something you can leave on the plate. Roti canai every morning before work is one of the commonest hidden contributors we find. Twice a week, or swapping some mornings for thosai, idli, plain roti without the extra oil, or nasi lemak with a smaller scoop of rice, changes the weekly total considerably without demanding misery. Palm oil is unavoidable in Malaysian cooking and we will not pretend otherwise; using less of it and steaming or grilling more is what helps. Kuih, teh tarik made with condensed milk, and mamak supper at eleven at night matter more for triglycerides and weight than for LDL, which brings us to the next section. Small substitutions kept up for years beat dramatic restrictions abandoned in a fortnight.

Triglycerides behave very differently from LDL and confuse people because of it. Patients who have carefully cut out fried food are baffled to find them still high. The explanation is that triglycerides respond far more to sugar, refined carbohydrate and alcohol than to dietary fat. The liver converts excess carbohydrate into triglyceride, so the drivers we find in practice are large rice portions at every meal, bread and biscuits between meals, and above all sweet drinks. Teh tarik and kopi with condensed milk carry a great deal of sugar, and three or four a day is common. Sirap bandung, canned soft drinks, packet juices and cendol compound it. Reducing sweetened drinks alone often produces a bigger fall than any other single change, and it costs nothing. Alcohol is disproportionately potent here. Even moderate regular drinking raises triglycerides noticeably in susceptible people, and where levels are very high it can be the dominant factor. A period of complete abstinence is not a moral instruction but a diagnostic experiment, and the repeat result usually makes the point better than any argument from us. Timing matters too. Eating a substantial meal at midnight and sleeping on it — entirely normal for shift workers around the Pasir Gudang industrial belt — worsens both triglycerides and weight. Shifting the largest meal earlier, where the shift pattern allows it, helps. There is one situation where triglycerides stop being a slow cardiovascular concern and become an urgent one. At extremely high levels they can inflame the pancreas, causing acute pancreatitis: severe abdominal pain boring through to the back with vomiting, and a hospital admission rather than a clinic problem. A very high triglyceride result is one to act on promptly rather than file away.

Lifestyle advice is often delivered as though it were an alternative to medication. Usually it is not an alternative; it is what makes medication work in a body that is not simultaneously working against it. Its effects are real, and worth being precise about. Exercise does relatively little to LDL directly. It works on triglycerides, which fall meaningfully with regular activity, on HDL, which rises modestly, on blood pressure, on insulin sensitivity, and on the abdominal fat driving the whole metabolic picture. The practical target most people can reach is around a hundred and fifty minutes a week of moderate activity — brisk walking counts, and in this climate that realistically means early morning or after dark. Laps of the neighbourhood after dinner, the stairs at work, or a badminton evening twice a week are all legitimate. Something imperfect done for years beats a gym membership used for six weeks. Weight is best tracked at the waist rather than on the scale. Fat carried around the abdomen is metabolically active and drives insulin resistance, high triglycerides, low HDL and the small dense LDL particles that are particularly atherogenic. Asian populations develop these problems at lower body weights than European ones, which is why someone who does not look heavy can still show a clearly metabolic lipid pattern. Losing five to ten percent of body weight shifts the whole profile. Smoking deserves the last word for how it interacts with cholesterol rather than how it changes the numbers. It damages the lining of the arteries, making them far more receptive to the LDL circulating past, lowers HDL, and makes blood more prone to clotting. In a smoker with raised cholesterol the two risks do not add, they multiply. Nothing else available to you reduces cardiovascular risk as much as stopping, and we would rather help you with that than double a tablet dose.

Patients often arrive braced for an argument about statins, having read a great deal online. We would rather have the conversation properly than wave it away, because dismissal is exactly why people stop taking tablets without telling anyone. Statins reduce the liver enzyme that manufactures cholesterol, which prompts the liver to pull more LDL out of the bloodstream. They also appear to stabilise existing plaque, making it less likely to rupture and trigger a clot. The benefit is proportional to how far the LDL falls and to how much risk you started with, which is the whole reason we assess risk before prescribing. In someone who has already had a heart attack, few patients need treating to prevent another event and the case is overwhelming. In a low-risk forty-year-old the same tablet prevents far less, and it is entirely legitimate to decide the balance is not yet worth it. Muscle aches are the concern raised most often, and they deserve a careful answer rather than a reassuring one. Genuine statin-related muscle symptoms exist and we take them seriously; severe muscle injury is real but rare. However, blinded trials, where neither patient nor doctor knew who was taking the drug, consistently found muscle symptoms at nearly the same rate on placebo — aches are simply common in middle age. That is the nocebo effect, and naming it is not calling anyone a liar. We settle it with a personal trial: stop, see whether the aches truly resolve over several weeks, then restart the same or a different one and watch. Many people certain they could not tolerate statins do fine on rechallenge, and those who genuinely cannot deserve a different plan rather than a lecture. On the other worries: significant liver injury is rare, and we check enzymes appropriately rather than reflexively. There is a small increase in the chance of crossing into diabetes, concentrated in people already close to that line, and in them the cardiovascular benefit still comfortably outweighs it. The memory and dementia claims have been examined repeatedly and have not held up. Tell us what you are experiencing; we will work through it rather than around it.

A statin is the usual first step, but it is not the only tool, and there are several reasons to reach for something else or something additional. Ezetimibe works by a completely different mechanism, reducing absorption of cholesterol from the gut rather than its manufacture in the liver. Because the two mechanisms are independent, adding it to a statin produces a further fall, and it is a reasonable option in its own right for someone who genuinely cannot take a statin after a proper trial. Fibrates target triglycerides specifically. Their real value is in the patient whose triglycerides are high enough to threaten the pancreas, where the priority is preventing pancreatitis rather than shaving LDL. Their role purely to reduce cardiovascular events in someone whose LDL is already controlled is more limited, and combining them with a statin needs care because of the muscle interaction. That decision is not one to make from a website. There are also newer injectable therapies that lower LDL dramatically, given every few weeks or, for some agents, only a few times a year. They are transformative for patients with familial hypercholaesterolaemia and for those with established heart disease who cannot reach an acceptable level on oral treatment. Access in Malaysia runs through specialist services, and our role is to identify who should be referred rather than leave them stranded on a maximum statin dose that is not enough. Omega-3 preparations, plant sterol spreads and red yeast rice come up regularly. Some have modest, specific roles; supplements bought online without knowing dose or purity are a different matter, and red yeast rice in particular contains a naturally occurring statin-like compound, giving statin-like effects without statin-like quality control. Bring the bottle and show us rather than taking it quietly alongside what we prescribe.

This is where a large share of treatment quietly falls apart, in a predictable sequence. A patient starts treatment. Three months later the repeat profile looks reassuring. They conclude, entirely logically, that the problem has been dealt with, and the tablets stop — sometimes after a conversation, more often without one. A year or two later they return with a report identical to the one they started with, feeling the treatment failed them. It did not fail. The number is normal precisely because of the tablet. A statin does not repair the underlying tendency; it counteracts it every day it is taken. Withdraw it and the liver goes back to doing what it always did, and within weeks the cholesterol drifts back to where it began. A good result is evidence the treatment is working, not evidence it is no longer needed. It is the pump keeping water out of a boat: a dry floor is not proof the leak has sealed itself. There is a subtler version of the same mistake. Someone improves their diet, takes up walking, loses weight, sees better numbers, and concludes the lifestyle changes have replaced the drug. In genuinely low-risk people who have made substantial and durable changes, reducing or stopping is a perfectly reasonable discussion — but it is a discussion, made with the risk picture in front of us and followed by a repeat test to see what actually happened. Done silently, nobody finds out for years. So the request is simple. If you want to come off treatment, if the cost is a burden, if you are having a side effect, if you are pregnant or planning to be, or if you have simply lost confidence in the plan, say so. Every one of those has a workable answer. None is helped by stopping without telling us.

A question we field constantly is whether you have to fast before a lipid test. For most purposes, no. Non-fasting samples are perfectly acceptable for screening and routine monitoring; the cholesterol fractions barely move with a meal, and triglycerides rise only modestly. Practically this is a relief, because a working person can have blood taken on the way home rather than arriving hungry at eight in the morning. Fasting still has its place. If triglycerides are markedly raised, if we are tracking a triglyceride problem over time, or if the LDL is calculated rather than measured and precision matters for a treatment decision, a nine to twelve hour fast with water only gives a cleaner picture. We will tell you which we want; you should not have to guess. On intervals: when starting or changing a lipid-lowering medication, a repeat profile roughly two to three months later shows whether the dose did what we intended, and that is also when we would check liver enzymes if indicated. Once you are stable at the level we agreed, annual review is usually sufficient, with a lower threshold if something changes — new diabetes, weight gain, a new medication, pregnancy, or a family event that shifts your risk picture. For low-risk screening with a good result, several years between tests is often entirely reasonable. One caution about single results. A panel taken during or shortly after an acute illness, a hospital admission, a heart attack or major surgery can mislead, and thyroid disease, kidney disease and certain medications all shift the profile. We read the trend across several results alongside everything else we know about you, rather than reacting to one line on one day. Klinik Muhibbah runs the lipid profile and the sixty-plus other blood tests on our own premises, along with ECG, ultrasound and X-ray, so investigating a cardiovascular concern does not become a tour of separate laboratories.

Cholesterol produces no sensations. There is no headache that means it is high, no tiredness that means it is climbing, no feeling that tells you a plaque has grown. It stays silent for as long as it takes, usually decades, and then it is not silent at all — because for far too many people the first symptom of high cholesterol is the event it caused. So know these, and make sure the people you live with know them too. Call 999 or go straight to the nearest emergency department if there is chest pain, pressure, tightness or heaviness, particularly if it spreads to the jaw, neck, back or an arm, or comes with sweating, nausea or breathlessness. Go if there is sudden breathlessness without an obvious cause. Go if there is sudden weakness or numbness of the face, arm or leg, especially on one side; if the face droops; if speech becomes slurred or the words will not come; if vision is suddenly lost or doubled. Treatment for stroke and heart attack is measured in minutes, and tissue lost while someone waits to see whether it settles is not recovered. Do not drive yourself, and do not wait for a clinic to open. For everything short of that, we are here. Klinik Muhibbah has looked after families in Masai since 1975, at No. 62 Jalan Kiambang, Taman Bunga Raya, 81700 Masai, Johor. Reception takes calls on +60 7-251 1162, and WhatsApp reaches us at +60 17-500 7205. We open Monday to Thursday and Saturday from 9AM to 9PM, Friday 9AM to 3PM, and Sunday 9AM to 1PM. You will see Dr. Prabagaran Kanapathy (M.D UNPAD, OHD NIOSH, MMC 63651) or Dr. Kirubah Sai Patnaik (MMC 93850), and appointments can be booked at movo-x.com/kiosk/muhibbah. If what you need is a discussion of results already in hand, a review of how treatment is being tolerated, or a repeat prescription while things are steady, a teleconsultation at RM30 prepaid handles that well, with medication delivered anywhere within Johor state. A first assessment, an examination and the bloods themselves are better done with you in the room.